Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration said today that it has approved a drug developed by Agios Pharmaceuticals for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with IDH1 mutations, as well as companion diagnostic test developed by Abbott Laboratories.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.